HomeCompareCYT vs NNN

CYT vs NNN: Dividend Comparison 2026

CYT yields 66.23% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYT wins by $854.5K in total portfolio value
10 years
CYT
CYT
● Live price
66.23%
Share price
$3.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$880.0K
Annual income
$221,634.45
Full CYT calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — CYT vs NNN

📍 CYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYT + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYT pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYT
Annual income on $10K today (after 15% tax)
$5,629.14/yr
After 10yr DRIP, annual income (after tax)
$188,389.28/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, CYT beats the other by $186,160.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYT + NNN for your $10,000?

CYT: 50%NNN: 50%
100% NNN50/50100% CYT
Portfolio after 10yr
$452.7K
Annual income
$112,128.56/yr
Blended yield
24.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

CYT
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Price Target
$2.00
-33.8% upside vs current
Range: $2.00 — $2.00
Altman Z
9.4
Piotroski
1/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYT buys
0
NNN buys
0
No recent congressional trades found for CYT or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTNNN
Forward yield66.23%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$880.0K$25.5K
Annual income after 10y$221,634.45$2,622.67
Total dividends collected$742.8K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$2.00$44.93

Year-by-year: CYT vs NNN ($10,000, DRIP)

YearCYT PortfolioCYT Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$17,323$6,622.52$10,735$614.96+$6.6KCYT
2$29,256$10,721.37$11,572$708.43+$17.7KCYT
3$48,227$16,923.00$12,531$819.53+$35.7KCYT
4$77,675$26,071.48$13,633$952.29+$64.0KCYT
5$122,356$39,243.54$14,909$1,111.84+$107.4KCYT
6$188,694$57,773.40$16,392$1,304.77+$172.3KCYT
7$285,170$83,268.01$18,129$1,539.52+$267.0KCYT
8$422,742$117,609.16$20,173$1,827.08+$402.6KCYT
9$615,273$162,940.02$22,597$2,181.81+$592.7KCYT
10$879,977$221,634.45$25,491$2,622.67+$854.5KCYT

CYT vs NNN: Complete Analysis 2026

CYTStock

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Full CYT Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this CYT vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYT vs SCHDCYT vs JEPICYT vs OCYT vs KOCYT vs MAINCYT vs ADCCYT vs EPRTCYT vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.